Fresenius Kabi expands production site for medical devices in Dominican Republic

April 20, 2018

Fresenius Kabi has started work on a major expansion of its production site for medical devices in Haina, Dominican Republic, which will create about 500 new jobs. At a groundbreaking ceremony yesterday attended by the country’s President Danilo Medina, the cornerstone was laid for the approximately 7,400-square-meter (80,000-square-foot) expansion. It will significantly increase capacity in Haina through the addition of new plasma kit assembly lines, injection molding equipment, sterilization units and dedicated warehouse space.

Completion of the expansion is scheduled for late 2019. The new employees, including production workers, technical personnel, engineers and managers, will join a Fresenius Kabi workforce in Haina that currently numbers about 3,000. The total investment is more than €20 million ($25 million).

The Haina plant manufactures and exports apheresis systems for plasma and platelet collection as well as medical devices for blood separation. These products are used, for example, to allow blood components to be separated while the blood is being donated, making it possible for these life-saving donations to be used more quickly and efficiently.

Mats Henriksson, CEO of Fresenius Kabi, said the products manufactured by the company in the Dominican Republic are important in the provision of healthcare far beyond the country. “Our employees here in Haina do an excellent job, and will continue to produce high-quality medical devices that provide healthcare professionals with the equipment they need to help their patients,” Henriksson said.

Also on hand for the ceremony was Dr. Christian Hauer, President Medical Devices Division of Fresenius Kabi. “This expansion will enable us to reach new potential in regard to our production capacities,” Hauer said. “Our strong commitment to our production site in Haina will benefit even more patients, and allow us to play an even greater role in improving the lives of chronically and critically ill people around the world.”

Fresenius Kabi expands production site for medical devices

Front row from left to right: Bernardo Alvarez, General Plant Manager Haina, Christian Hauer, Board Member of Fresenius Kabi and President of the Medical Devices Division, Mats Henriksson, CEO of Fresenius Kabi, Danilo Medina, President of the Dominican Republic, Manuel Tavares, CEO PIISA Industrial Park, Luisa Fernandez, Free Zone Council Director, Nelson Toca, Minister of Commerce and Industry of the Dominican Republic, Ramon Fadul, Labor Minister of the Dominican Republic, Tommy Galan, Senator of San Cristobal Province


Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases. With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Fresenius Kabi employs over 36,000 people worldwide. In 2017 the company reported sales of more than €6 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

For more information visit the Company’s website at

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Mats Henriksson (Chairman), Marc Crouton, John Ducker, Dr. Christian Hauer, Dr. Michael Schönhofen, Philipp Schulte-Noelle, Gerrit Steen
Chairman of the Supervisory Board: Stephan Sturm
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg - HRB 11654